- Home
- SCNX vs ALXO Comparison
SCNX vs ALXO Comparison
Compare SCNX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- ALXO
- Stock Information
- Founded
- SCNX 2010
- ALXO 2015
- Country
- SCNX United States
- ALXO United States
- Employees
- SCNX N/A
- ALXO N/A
- Industry
- SCNX Other Pharmaceuticals
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- ALXO Health Care
- Exchange
- SCNX Nasdaq
- ALXO Nasdaq
- Market Cap
- SCNX 21.2M
- ALXO 24.0M
- IPO Year
- SCNX 2020
- ALXO 2020
- Fundamental
- Price
- SCNX $1.21
- ALXO $0.64
- Analyst Decision
- SCNX
- ALXO Strong Buy
- Analyst Count
- SCNX 0
- ALXO 6
- Target Price
- SCNX N/A
- ALXO $3.30
- AVG Volume (30 Days)
- SCNX 330.0K
- ALXO 563.3K
- Earning Date
- SCNX 08-12-2025
- ALXO 08-12-2025
- Dividend Yield
- SCNX N/A
- ALXO N/A
- EPS Growth
- SCNX N/A
- ALXO N/A
- EPS
- SCNX N/A
- ALXO N/A
- Revenue
- SCNX $128,202.00
- ALXO N/A
- Revenue This Year
- SCNX N/A
- ALXO N/A
- Revenue Next Year
- SCNX N/A
- ALXO N/A
- P/E Ratio
- SCNX N/A
- ALXO N/A
- Revenue Growth
- SCNX N/A
- ALXO N/A
- 52 Week Low
- SCNX $0.69
- ALXO $0.40
- 52 Week High
- SCNX $10.23
- ALXO $2.79
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- ALXO 57.73
- Support Level
- SCNX N/A
- ALXO $0.60
- Resistance Level
- SCNX N/A
- ALXO $0.69
- Average True Range (ATR)
- SCNX 0.00
- ALXO 0.06
- MACD
- SCNX 0.00
- ALXO 0.00
- Stochastic Oscillator
- SCNX 0.00
- ALXO 63.95
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.